The need for a men's health initiative

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 58, Issue 7, 2003, Pages 614-617

  Morley, John E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; LEPTIN; LUTEINIZING HORMONE; PRASTERONE; SILDENAFIL; TESTOSTERONE;

AGING; BODY FAT; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG SAFETY; EDITORIAL; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOTHALAMUS; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT;

EID: 0041343247     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/58.7.m614     Document Type: Editorial

References (90)

1. University of Maryland at Baltimore, Coronary Drug Project Research Group, The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA. 1973;226:652-657.
2. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol Med Sci. 2002;57A:M76-M99.
3. Morley JE. Andropause: is it time for the geriatrician to treat it? J Gerontol Med Sci. 2001;56A:M263-M265.
4. Morley JE, Kaiser FE, Perry HM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metab Clin Exper. 1997;46:410-413.
5. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrin Metab. 2001;86:724-731.
6. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589-598.
7. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epid. 1997;146:609-617.
8. Keenan DM, Veldhuis JD. Disruption of the hypothalamic luteinizing hormone pulsing mechanisms in aging men. Am J Physiol Regulat Integr Compar Physiol. 2001;281:R1917-R1924.
9. Morley JE. Androgens and aging. Maturitas. 2001;38:61-71.
10. Morley JE, Perry HM III. Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med. 2000;135:370-378.
11. Morley JE, Patrick P, Perry HM. Evaluation of assays available to measure free testosterone. Metab Clin Exper. 2002;51:554-559.
12. Kenny AM, Prestoowd KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Med Sci. 2001;56A:M266-M272.
13. Christmas C, O'Connor KG, Harman SM, et al. Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J Gerontol Med Sci. 2002;57A: M12-M18.
14. Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6 tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial. J Gerontol Med Sci. 2003;58A:165-170.
15. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092-1098.
16. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966-1972.
17. Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men - a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661-1667.
18. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:2647-2653.
19. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc. 2003;51:101-115.
20. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Med Sci. 2003;58A:618-625.
21. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001;137:231-243.
22. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol Med Sci. 2000;55A:M716-M724.
23. Baumgartner, Rn Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mechanisms Ageing Devel. 1999;107:123-136.
24. Baumgartner RN, Waters DL, Morley JE, Patrick P, Montoya GD, Garry PJ. Age-related changes in sex hormones affect the sex difference in serum leptin independently of changes in body fat. Metabol Clin Exper. 1999;58:378-384.
25. Iannuzzi-Sucich M, Prestwood KM, Kenny Am. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol Med Sci. 2002;57A:M772-M777.
26. van den Beld AW, de John FH, Grobbee DE, Pols HAP, Lamberts SWJ. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85:3276-3282.
27. Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab. 2002;283:E284-E294.
28. Schiavi RC, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med. 1991;53:363-374.
29. Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA. 1983;249:1736-1740.
30. Morley JE, Kaiser FE. Impotence: the internist's approach to diagnosis and treatment. Adv Intern Med. 1993;38:151-168.
31. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males - a retrospective analysis. J Clin Endocrinol Metab. 1997;82:3793-3796.
32. Morales A, Johnston B, Heaton JPW, Lundie M. Testosterone supplementation for hypogonadal impotence - assessment of biochemical measures and therapeutic outcomes. J Urology. 1997;157:849-854.
33. Wagner G, Montorsi F, Auerbach S, Collins M. Sildenafil citrate (Viagra) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol Med Sci. 2001;56A: M113-M119.
34. Tariq SH, Haleem U, Omran ML, Kaiser FE, Perry HM III, Morley JE. Erectile dysfunction: etiology and treatment in young and old patients. Clin Geriatrics. In press.
35. Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57A:80-88.
36. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J Gerontol Med Sci. 2002;57A:M321-M325.
37. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences cognition in older men. Behav Neurosci. 1994;108:325-332.
38. Asthana S. Estrogen and cognition: the story so far [Guest Editorial]. J Gerontol Med Sci. 2003;58A:322-323.
39. Whitmer RA, Haan MN, Miller JW, Yaffe K. Hormone replacement therapy and cognitive performance: the role of homocysteine. J Gerontol Med Sci. 2003;58A:324-330.
40. Gonzales McNeal M, Zareparsi S, Camicioli R, et al. Predictors of healthy brain aging. J Gerontol Biol Sci. 2001;56A:B294-B301.
41. Ott BR, Belazi D, Lapane KL. Cognitive decline among female estrogen users in nursing homes. J Gerontol Med Sci. 2002;57A:M594-M598.
42. Leranth C, Petnehazy O, MacLusky NJ. Gonadal hormones affect spine synaptic density in the CA1 hippocampal subfield of male rats. J Neurosci. 2003;23:1588-1592.
43. Kritzer MF, McLaughlin PJ, Smirlis T, Robinson JK. Gonadectomy impairs T-maze acquisition in adult male rats. Hormones Behav. 2001;39:167-174.
44. Flood JF, Farr SA, Kaiser FE, Laregina M, Morley JE. Age-related decrease of plasma testosterone in SAMP8 mice - replacement improves age-related impairment of learning and memory. Physiol Behavior. 1995;57:669-673.
45. Morley JE, Kumar VB, Bernardo AE, et al. Beta-amyloid precursor polypeptide in SAP8 mice affects learning and memory. Peptides. 2000;21:1761-1767.
46. Kumar VB, Farr SA, Flood JF, et al. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides. 2000;21:1769-1775.
47. Morley JE, Farr SA, Kumar VB, Banks WA. Alzheimer's disease through the eye of a mouse - acceptance lecture for the 2001 Gayle A. Olson and Richard D. Olson prize. Peptides. 2002;23:589-599.
48. Hogevorst E, Lehmann DJ, Warden, Dr McBroom J, Smith AD. Apolipoprotein E epsilon 4 and testosterone interact in the risk of Alzheimer's disease in men. Int J Geriatr Psychiatr. 2002;17:938-940.
49. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Hannan SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87:5001-5007.
50. Jordan WP Jr, Blackard CE, Byar DP. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. Southern Med J. 1977;70:1411-1413.
51. Fowler JE Jr, Whitmore WF Jr. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer. 1982;49:1373-1377.
52. Morgentaler A, Bruning CO, Dewolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996;276:1904-1906.
53. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;57:52-58.
54. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999;80:930-934.
55. Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology. 2001;57:930-935.
56. Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma - a longitudinal study. Cancer. 1999;86:312-315.
57. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Baltimore Longitudinal Study on Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab. 2000;85:4258-4265.
58. Gooren LJ. Long-term safety of the oral androgen testosterone undecanoate. Int J Andrology. 1986;9:21-26.
59. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/Progestin Replacement Study follow-up (HERSII). JAMA. 2002;288:49-57.
60. Rossouw JE, Anderson GL, Prentice RI, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women - principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
61. van den Beld AW, Bots ML, Janssen JAMLL, Pols HAP, Lamberts SWJ, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157:25-31.
62. English KM, Mandour O, Steeds RP, Diver MJ, Jones RH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms - reply [Letter]. Eur Heart J. 2001;22:613.
63. English KM, Steeds R, Jones TH, Channer KS. Testosterone and coronary heart disease - is there a link? WJM Monthly J Assoc Physicians. 1997;90:787-791.
64. English KM, Steeds RP, Jones RH, Diver MJ, Channer KS. Lower-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina - a randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906-1911.
65. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol. 2000;85:269-272.
66. Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B, Mansoor G. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol Med Sci. 2002;57A:M460-M465.
67. 2 peak. J Gerontol Med Sci. 2002;57A:M203-M208.
68. Wiswell RA, Hawkins SA, Jaque SV, et al. Relationship between physiological loss, performance decrement, and age in master athletes. J Gerontol Med Sci. 2001;56A:M618-M626.
69. Anderson JK, Faulkner S, Cranor C, Briley J, Gevirtz F, Roberts S. Andropause: knowledge and perceptions among the general public and health care professionals. J Gerontol Med Sci. 2002;57A: M793-M796.
70. Mortey JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metab Clin Exper. 2000;59:1239-1242.
71. DeFrancesco L. Prostate cancer prevention trial launched [News Item]. Nature Med. 2001;7:1076.
72. Lan TY, Melzer D, Tom BDM, Guralnik JM. Performance tests and disability: developing an objective index of mobility-related limitation in older populations. J Gerontol Med Sci. 2002;57A:M294-M301.
73. Sicard-Rosenbaum L, Light KE, Behrman AL. Gait, lower extremity strength, and self-assessed mobility after hip arthroplasty. J Gerontol Med Sci. 2002;27A:M47-M51.
74. Jylha M, Guralnik JM, Balfour J, Fried LP. Walking difficulty, walking speed, and age as predictors of self-rated health: the women's health and aging study. J Gerontol Med Sci. 2001;56A:M609-M617.
75. Simonsick EM, Newman AB, Nevitt MC, et al. Measuring higher level physical function in well-functioning older adults: expanding familiar approaches in the health ABC study. J Gerontol Med Sci. 2001;56A: M644-M649.
76. Morley JE. Mobility performance: a high tech test for geriatricians [Editorial]. J Gerontol Med Sci. In press.
77. Morley JE, Perry HM, Miller Dk. Something about frailty. J Gerontol Med Sci. 2002;57A:M698-M704.
78. Metter EJ, Talbot LA, Schrager M, Conwit R. Skeletal muscle strength as a predictor of all-cause mortality in healthy men. J Gerontol Biol Sci. 2002;57A:B359-B365.
79. Bortz WM. A conceptual framework of frailty: a review. J Gerontol Med Sci. 2002;57A:M283-M288.
80. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Med Sci. 2001;56A:M146-M156.
81. Perry HM, Miller, Dk Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metab Clin Exper. 2000;59:1085-1091.
82. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001;137:231-243.
83. Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc. 2000;58:550-553.
84. Evans WJ. Exercise as the standard of care for elderly people. J Gerontol Med Sci. 2002;57A:M260-M261.
85. Singh MAF. Exercise comes of age: rationale and recommendations for a geriatric exercise prescription. J Gerontol Med Sci. 2002;57A:M262-M282.
86. Westerterp KR, Meijer EP. Physical activity and parameters of aging: A physiological perspective. J Gerontol Biol Sci Med Sci. 2001;56 (Special Issue 2):7-12.
87. King AC. Interventions to promote physical activity by older adults. J Gerontol Med Sci. 2001;56(Special Issue 2):36-46.
88. Bartke A, Coschigano K, Kopchick J, et al. Genes that prolong life: relationships of growth hormone and growth to aging and life span. J Gerontol Biol Sci. 2001;56A:B340-B349.
89. Morley JE. Growth hormone: fountain of youth or death hormone? J Am Geriatr Soc. 1999;47:1475-1476.
90. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:4279-4284.